10-Q: ZimVie Agrees to $19.00 Per Share Acquisition by ARCHIMED Affiliate Amidst Improved Operating Performance

ZimVie Inc. has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash, representing a 99% premium, while reporting improved operating profit and reduced net loss for the second quarter and first half of 2025.

Summary

• ZimVie Inc. has agreed to be acquired by Zamboni Parent Inc., an affiliate of ARCHIMED, for $19.00 per share in cash.
• The acquisition price represents a 99% premium over ZimVie's 90-day volume-weighted average price of $9.57 per share as of July 18, 2025.
• The merger is expected to close by year-end 2025, subject to stockholder and regulatory approvals.
• For the three months ended June 30, 2025, net sales were $116.662 million, a slight decrease from $116.811 million in the prior year period.
• Operating profit significantly improved to $1.291 million for Q2 2025, compared to an operating loss of $6.687 million in Q2 2024.
• Net loss from continuing operations decreased to $3.849 million for Q2 2025, down from $9.553 million in Q2 2024.
• For the six months ended June 30, 2025, net sales were $228.659 million, a decrease from $235.006 million in the prior year period.
• Operating profit for the six months ended June 30, 2025, was $2.071 million, a substantial improvement from an operating loss of $9.498 million in the same period last year.
• Net loss from continuing operations for the six months ended June 30, 2025, was $6.474 million, a significant reduction from $21.114 million in the prior year period.
• The company completed the sale of its spine segment on April 1, 2024, for $377.0 million, receiving $311.6 million in cash proceeds and a $60.0 million promissory note.
• Proceeds from the spine segment sale were used to prepay $275.0 million of the Term Loan, eliminating scheduled quarterly amortization payments.
• Cash and cash equivalents stood at $70.176 million as of June 30, 2025, down from $74.974 million at December 31, 2024.
• Total debt was $220.786 million as of June 30, 2025.

Sentiment

Score: 8

Explanation: The proposed acquisition at a substantial 99% premium is a highly positive development for shareholders, overshadowing the mixed operational results. While sales slightly declined, the company showed significant improvement in operating profit and reduced net loss from continuing operations, indicating better cost management and efficiency post-spine divestiture. The pending privatization removes public market pressures and offers a clear exit for current shareholders at a favorable valuation.

Positives

• Operating profit significantly improved to $1.291 million for the three months ended June 30, 2025, from a loss of $6.687 million in the prior year.
• Net loss from continuing operations decreased to $3.849 million for the three months ended June 30, 2025, from $9.553 million in the prior year.
• Cost of products sold as a percentage of net sales improved to 35.4% for Q2 2025 from 37.3% in Q2 2024, driven by manufacturing efficiencies.
• Research and development (R&D) expenses decreased by $0.9 million in Q2 2025 due to reduced headcount and share-based compensation.
• Selling, general and administrative (SG&A) expenses decreased by $2.8 million in Q2 2025 due to reduced professional fees and compensation.
• Interest expense decreased due to a reduction in outstanding debt following the $275.0 million prepayment on the Term Loan in April 2024.
• The proposed acquisition by ARCHIMED offers a substantial 99% premium to shareholders based on the 90-day volume-weighted average price.
• The company acquired the dental business of its distributor in Costa Rica for $3.3 million, expanding its dental segment.

Negatives

• Net sales slightly decreased by 0.1% for the three months ended June 30, 2025, and by 2.7% for the six months ended June 30, 2025, compared to prior year periods.
• Volume/mix trends showed decreases in sales of dental implant systems and biomaterial products, and were impacted by the exit of a transition manufacturing agreement.
• Experienced price declines, primarily on premium dental implant system sales in the U.S.
• Continued to report a net loss of $3.947 million for the three months ended June 30, 2025, and $5.418 million for the six months ended June 30, 2025.
• Cash flows used in operating activities increased to $10.682 million for the six months ended June 30, 2025, from $8.475 million in the prior year, primarily due to working capital changes.
• Other income, net, decreased due to a reduction in Transition Services Agreement (TSA) income related to the spine segment sale.

Risks

• The proposed merger may not be completed in a timely manner or at all, due to conditions such as stockholder approval, regulatory approvals (Hart-Scott-Rodino Antitrust Improvements Act, non-U.S. antitrust/foreign direct investment approvals), and absence of legal restraints.
• Failure to complete the merger could lead to a significant decline in stock price, payment of termination fees ($10.1 million or $20.2 million), substantial incurred costs, limitations on retaining key personnel, reputational harm, and business disruption.
• The pendency of the merger could negatively impact business operations, financial condition, and results, potentially causing customers and business partners to delay decisions or end relationships.
• Uncertainty about future roles due to the merger may adversely affect the ability to attract and retain key personnel.
• Restrictions in the merger agreement may prevent the company from pursuing beneficial business opportunities or making changes to its business or organizational structure prior to completion.
• Changes in U.S. trade policy, including the imposition of tariffs (e.g., 10% tariff announced April 2, 2025), could materially impact business, financial condition, and results of operations, potentially increasing costs for products manufactured in Spain.
• Exposure to foreign currency exchange rate risk, particularly with Euros and Japanese Yen, could adversely affect financial condition, results of operations, and cash flows.
• The ability to collect accounts receivable in some countries, especially in Europe, depends on the financial stability of public hospitals and national healthcare systems, exposing the company to government budget constraints.
• Ongoing litigation with a spine products distributor in China related to the 2022 exit of the China spine business has resulted in $1.7 million in restricted cash.

Future Outlook

The company expects the proposed merger with Zamboni Parent Inc., an affiliate of ARCHIMED, to be consummated by year-end 2025, subject to stockholder and regulatory approvals. It is also evaluating the effects of the recently enacted One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements. Restructuring activities initiated in January 2024 to optimize the organization are expected to be completed by the end of 2025.

Management Comments

• We believe we are well-positioned in the growing global dental implant and digital dentistry market with a strong presence in the tooth replacement market and market leading positions in certain geographies.
• We are taking actions to optimize our internal distribution and supply activities to mitigate the impact of new U.S. tariffs.
• We believe that available cash and cash equivalents, cash flows generated through operations and cash available under our revolving credit facility will be sufficient to meet our liquidity needs, including capital expenditures, for at least the next 12 months.

Industry Context

The dental technology industry continues to see demand for tooth replacement and restoration procedures, with growth in dental implants and digital dentistry solutions. ZimVie's strategic shift to focus solely on its dental segment, following the divestiture of its spine business, positions it as a specialized player in this market. The proposed acquisition by ARCHIMED, a private equity firm specializing in healthcare, indicates a potential move towards private ownership to further optimize operations and capitalize on market opportunities away from public market pressures. The industry faces challenges from pricing pressures, regulatory requirements (e.g., EU MDR), and global trade policies, including new tariffs.

Corporate Governance

Legal Proceedings

• Subject to various claims, legal proceedings, and investigations related to product liability, intellectual property, and commercial matters in the normal course of business.
• Currently, the outcome of these matters is not expected to have a material adverse impact on results of operations, cash flows, or financial position.
• Accrual balance for loss contingencies decreased to $0.1 million as of June 30, 2025, from $2.2 million as of December 31, 2024, primarily due to a payment in January 2025 for a settled matter.
• Assumed liability for all pending and threatened legal matters related to the spine business and will indemnify Zimmer Biomet for such liabilities.
• Ongoing litigation in China with a spine products distributor has resulted in $1.7 million in restricted cash.

Stakeholder Impact

• Shareholders: Significant positive impact due to the proposed acquisition at a 99% premium, offering a clear cash exit.
• Employees: Potential uncertainty regarding future roles and employment following the merger, as well as ongoing impacts from restructuring activities (reduced headcount, compensation changes).
• Customers: Potential for disruption or changes in relationships due to the pending merger, though the company aims to maintain relationships.
• Suppliers: Potential for disruption or changes in relationships due to the pending merger.
• Creditors: The company remains in compliance with debt covenants, and the debt prepayment from the spine sale improved its debt profile. The merger will likely impact the debt structure post-closing.

Next Steps

• Seek approval from stockholders for the proposed merger.
• Obtain required regulatory approvals for the merger, including expiration or early termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and non-U.S. antitrust/foreign direct investment approvals.
• Complete the merger with Zamboni Parent Inc. by year-end 2025.
• Continue evaluating the effects of the One Big Beautiful Bill Act (OBBBA) on financial statements.
• Complete restructuring activities initiated in January 2024 by the end of 2025.

Key Dates

Recommendation

The announcement of a definitive merger agreement at a significant premium of $19.00 per share means the stock price will likely trade close to this offer price, minus any discount for the time value of money and deal completion risk. For investors who own the stock, holding until the merger closes to receive the cash consideration is generally the recommended strategy, assuming the deal is expected to close. Selling now would realize the current market price, which should be near the offer, while buying now would only yield the $19.00 per share if the deal closes, with limited upside and downside risk if the deal fails. Therefore, 'hold' is appropriate for existing shareholders awaiting the cash payout.

Keywords

Dental Implants, Medical Technology, Acquisition, Merger, SEC Filing, 10-Q, Financial Results, Dental Biomaterials, Digital Dentistry, Healthcare, ZimVie, ARCHIMED, Corporate Governance, Risk Factors, Financial Performance